No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Jan. 9, 2024 (HealthDay News) — For individuals with overweight or obesity and type 2 diabetes, semaglutide is not associated with an increased risk for suicidal ideation compared with non-glucagon-like peptide 1 receptor (GLP1R) agonist antiobesity medications, according to a study published online Jan. 5 in Nature Medicine<\/em>.<\/p>\n William Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted a retrospective cohort study using electronic health records to examine the associations of semaglutide versus non-GLP1R agonist antiobesity medications with suicidal ideation. The study population included 240,618 patients with overweight or obesity; findings were replicated among 1,589,855 patients with type 2 diabetes.<\/p>\n The researchers found that the risks for incident and recurrent suicidal ideation were lower for patients with overweight or obesity receiving semaglutide versus non-GLP1R agonist antiobesity medications (hazard ratios, 0.27 and 0.44, respectively); the findings were consistent across sex, age, and ethnicity stratification. In patients with type 2 diabetes, similar findings were replicated.<\/p>\n “Further studies should evaluate the association of semaglutide and other GLP1R agonist medications with the incidence and recurrence of suicidality in other at-risk populations,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n